Predictive biomarkers for treatment response — the missing link in psoriatic arthritis clinical development
Year: 2026
Type: article
Abstract: Psoriatic arthritis (PsA) has more effective therapies than ever, yet drug selection still relies on trial and error. Across 1,155 interventional PsA trials (Trialtrove, March 2026), phase III–IV confirmatory studies account for half of all activity, but no validated biomarker predicts which patient will respond to which mechanism. Most patients cycle through two or more biological or targeted-synthetic disease-modifying antirheumatic drugs (DMARDs) before remission, and difficult-to-manage and treatment-refractory PsA have only recently been formally defined. Our central claim is that the main barrier to precision medicine in PsA is no longer drug availability but the absence of response-predictive biomarkers. Two roles must be distinguished. Prognostic markers such as C-reactive protein (CRP) and baseline joint erosions, which predict a higher risk of radiographic progression, are now routinely used to enrich phase 3 PsA trials; the APEX and POETYK PsA-1 programmes require both elevated high-sensitivity CRP and radiographically confirmed erosions. Because CRP elevation predicts better response across tumour necrosis factor, interleukin (IL)-17, IL-23 and tyrosine kinase 2 inhibition alike, however, it cannot discriminate between mechanisms: enrichment for risk is not selection by predicted benefit. Response prediction is feasible: COSMOS and DISCOVER substudies show baseline IL-22, IL-17A/F and IFNγ levels track later guselkumab response. We propose three steps: standardized biospecimen collection in phase 3 PsA trials, pre-specified mechanism-matched predictive panels, and—contingent on validated cross-tissue markers—biomarker-guided adaptive trials in difficult-to-treat PsA. Closing this gap is the decisive step toward treat-to-target precision medicine in PsA.
Source: Frontiers in Immunology
Institution: Jiaxing University
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: psoriatic arthritis, predictive biomarkers, treatment response prediction, precision medicine, disease-modifying antirheumatic drugs, guselkumab, IL-22, IL-17A/F, interferon-gamma, high-sensitivity C-reactive protein, joint erosions, adaptive clinical trials, treat-to-target, drug selection
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236387387
